Morrissey Michael James, an insider at Incyte Corp (INCY), sold 27,507 shares of the company on December 16, 2025, at a price of $97.26 per share, resulting in a total transaction value of $2.68 million. Following this sale, James retains 27,507 shares of Incyte.
Incyte Corp is a biopharmaceutical company based in Wilmington, Delaware, specializing in the discovery, development, and commercialization of proprietary therapeutics. The firm operates primarily in two therapeutic areas: Hematology/Oncology and Inflammation and Autoimmunity. Its portfolio includes notable products such as JAKAFI (ruxolitinib) and MONJUVI (tafasitamab-cxix), among others. As of November 20, 2025, Incyte boasts a market capitalization of $20.2 billion and a price-to-earnings ratio of 17.00, with an earnings per share of 5.91.
Insider selling can occur for various reasons, including diversification or personal financial needs. While large transactions may attract attention, they do not inherently signal negative sentiment towards the company. Investors are encouraged to consider insider activity as one of many factors in their analysis, looking for patterns across multiple insiders over time.
Insider transactions must be reported to the SEC, providing transparency into the actions of company executives and board members. Such sales represent a single data point that investors may weigh alongside other fundamental and technical indicators. Upcoming earnings for Incyte are projected for April 27, 2026, with an estimated EPS of $1.71 and revenue of $1.3 billion.